multivirus specific t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01070797)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Adenoviridae Infections · Phase 1
- Cytomegalovirus Infections · Phase 1
- Epstein-Barr Virus Infections · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
Mechanism of action
- BK virusImmunity, passive
BK virus immunity, passive
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
- Human adenovirusImmunity, passive
Human adenovirus immunity, passive
- epstein-barr virusImmunity, passive
epstein-barr virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- multi-virus specific t cells
- multivirus specific t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02231853 | Phase 1/Phase 2 (Phase 2) | Aug 22, 2014 | National Heart, Lung, and Blood Institute (NHLBI) |
| NCT02108522 | N/A | Jun 1, 2014 | Baylor University, Methodist Cancer Center, Houston, Texas, ViraCyte |
| NCT01070797 | Phase 1 | Jan 1, 2011 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 2 | 1 | 2 | 2011 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 2 | 0 | 2 | 2011 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 1 | 1 | 2014 |
| ViraCyte | For profit | 1 | 1 | 1 | 2014 |
4 organizations
Page 1 / 1